KR20190029324A - Compositions for anti-itching of skin comprising plant extracts - Google Patents

Abstract

The present invention relates to a composition for alleviating skin itching containing cornhusk and above-ground Centella asiatica extracts as active ingredients. The composition containing cornhusk and above-ground Centella asiatica extracts as active ingredients of the present invention inhibits the activation and expression transient receptor potential vanilloid type 1 (TRPV1), and interleukin-31 (IL-31) as well as freeing of histamine derived from itching mediators, thereby protecting skin from itching inducing factors to alleviate and inhibit skin itching. In addition, a composite extract is effective in measuring the degree of alleviation of itching and atopic dermatitis in a human body application test and has no side effect on a human body, thereby being safely used in cosmetic materials and pharmaceutical compositions.

Description

[0001] The present invention relates to a cosmetic composition for skin itching,

The present invention relates to a composition for relieving skin itching comprising an extract of a plant as an active ingredient, which comprises a complex extract of a corn husk and an extract of a ground part of a pathogen, The present invention relates to a cosmetic composition and a pharmaceutical composition for suppressing and relieving skin itching caused by an itch inducing factor by inhibiting activation of vanilloid type 1, TRPV1 and interleukin-31 (IL-31).

Itching is the most common symptom of skin disease, and physiological self-protection is a phenomenon that appears to protect the skin from harmful or irritating substances from the outside. Itching can be accompanied by pain, and even the same stimulus can sometimes cause a very different degree of itching depending on the person. Itching may occur with external stimulation and may occur in association with various skin diseases or medical and neurological diseases.

Itching caused by various causes causes secondary skin lesions such as wounds and rashes, and when it is scratched, itching secretion is secreted, causing a vicious cycle in which the itching becomes worse.

The skin and peripheral nerves have strong itching mediators and receptors, including the H4 histamine receptor, PAR-2, cathepsin S, interleukin-31, IL-31, transient receptor potential vaniloid type 1, TRPV1), nerve growth factor (NGF) and receptors, acetylcholine, and substance P.

On the other hand, mast cells are rich in granules in the cytoplasm and secrete mediators that are involved in the itching and rash of skin caused by external stimuli. Histamine, serine protease, which is already stored in the granules of mast cells and released when the stimulus is given, is a representative mediator. There are cytokines such as histamine, serine protease, Cytokine, leukotriene, prostaglandin, and the like. In particular, when histamine binds to vascular endothelial cells, vascular cell contraction occurs to excrete the plasma into the tissue, and endothelial cells release prostacyclin and nitric oxide, which relax vascular muscle cells. ( Yano et al ., J Clin Invest ., 1989; 84: 1276-86). In addition, it is possible to induce swelling, vomiting and irritation of the skin by inducing vasodilatation.

In addition, IL-31 has been known as one of the representative cytokines that play an important role in itching. Overexpression of IL-31 in lymphocytes is known to cause dermatitis as well as scratching, and it is known to increase in atopic dermatitis and skin lesions in patients with itchy rash. Recent gene mutations of the IL-31 receptor have been shown to be involved prior to the development of familial primary amyloidosis with localized itching, and it has been shown to act directly on receptors in the skin nerve fibers, leading to itching. In addition, the anti-IL-31 antibody reduced the scratching behavior of skin lesions in a mouse model of atopic dermatitis, confirming that IL-31 is an important mediator of itching. Therefore, the development of therapeutic agents targeting IL-31 is considered to be a major target in the treatment of inflammatory skin diseases, which manifest as atopic dermatitis and other itching.

Transient receptor potential vaniloid type 1 (TRPV1) is a non-selective cation channel with calcium permeability that detects various toxic chemical and thermal stimuli. Capsaicin acts on TRPV1 present in the sensory nerve to release neuropeptides such as substance P. Recently, it has been shown that TRPV1 is important in the pathogenesis of itch. Based on this, capsaicin is being used to treat itch. Therefore, development of a material targeting TRPV1 can be applied as a material that can reduce skin troubles, burning sensation, and feelings of atopic dermatitis patients and sensitive skin patients.

Currently, drugs commonly used to relieve itching and inflammation include antihistamines and steroid preparations. Side effects may occur if taken over a long period of time or when applied to the skin. Therefore, it is necessary to develop a material with minimal side effects that can effectively control the inflammatory reaction accompanied by itching.

On the other hand, corn ( Zea mays L.) is a tropical crop belonging to the Gramineae family. For medicinal purposes, corn roots and leaves were used to treat sick symptoms because of urination and urinary stones. In addition, corn bran or beard may be selected from the group consisting of ferulic acid, coumaric acid, N, N- dimeruloylputrescine, N, N- dicoumaroylputrescine, antioxidant, anti-obesity, and anti-aging, including physiologically active ingredients such as carotenoids, phytosterols, corn fiber, and maysin.

Centella asiatica ( Centella asiatica ) is a perennial plant belonging to the family Persia, and is known to be effective for fever, chewing or muscle spasms, Asiaticoside, a glycoside isolated from such a housepine, is known to be effective for skin ulcers, extensive trauma, skin veins, obliteration ulcers, erosive skin ulcers, and alopecia areata. However, in the case of skin itching relief and healing There is no report.

Accordingly, the present inventors have found that a mixture of corn husk extract and Centella asiatica B containing a large amount of Centella asiatica extract has an effect on skin pruritus while steadily conducting research on skin itching. Thus, .

SUMMARY OF THE INVENTION Accordingly, it is an object of the present invention to provide a composition containing a steroid and an antihistamine, which are used for inhibiting skin itching, and which has high human stability and is free from side effects of skin.

In order to solve the above technical problems, the present invention provides a composition for suppressing and alleviating itching of skin comprising an extract of corn husks and topical extracts of corn husks and corn cobs, at a weight ratio of 2: 1 to 1: 2, as an active ingredient.

Preferably, the composition in the present invention may be a cosmetic composition or a pharmaceutical composition.

In the present invention, prevention of skin itching means prevention of skin itching from all kinds of causes, and it is effective to prevent skin irritation from external stimuli or to improve and improve skin itching caused by various skin diseases or medical neurological diseases .

In the present invention, the complex extract means a mixture comprising a corn husk extract and a topical extract of a coriander. In the present invention, the extract of corn husk extract and the combination of the extracts of topical ginseng root extract to alleviate and inhibit skin itch, Respectively.

According to one embodiment of the present invention, the composition according to the present invention comprises a complex extract obtained by mixing corn husks and topical extracts of corn cobs and corn cob in a weight ratio of 2: 1 to 1: 2, preferably 1: 1, .

According to a preferred embodiment of the present invention, the bloody ground-portion extract is a fraction of a bloom-ground-portion extract containing a large amount of asiaticoside B contained in a bottle pool.

The term " extract " of the present invention refers to a preparation which is obtained by squeezing a herbal medicine with an appropriate leaching solution and concentrating the liquid by evaporating the leaching solution. The extract solution obtained by the extraction treatment, diluted solution of the extract solution, Dried products obtained by these methods, their controlled products or purified products.

Extracts in the present invention can be prepared using general extraction, isolation and purification methods known in the art. Examples of the extraction method include, but are not limited to, hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction.

According to a specific embodiment of the present invention, the extract of corn husks and the topical extract of corn husks may be prepared by drying the ground corn husks and corn husks and then pulverizing them and extracting them using water, an organic solvent or a mixture thereof, followed by filtration under reduced pressure. In this case, examples of the organic solvent include methanol, ethanol, propanol or butanol, preferably ethanol, more preferably 70% ethanol.

According to one embodiment of the present invention, the fraction of the topical extract of Aspergillus oryzae containing a large amount of Asiaticoside B is obtained by dissolving the topical extract of the topical extract of the perilla organs in an organic solvent, filtering and then using the organic solvent and water as a mobile phase, Can be obtained through a further extraction process which performs liquid chromatography (HPLC). Examples of the organic solvent include methanol, ethanol, propanol, and butanol.

In the present invention, the above-mentioned " active ingredient " means a component that exhibits the desired activity alone or can exhibit activity together with a carrier which is itself inactive.

The composition of the present invention may contain the complex extract in an amount of 0.00001 to 15.0% by weight, more preferably 0.0001 to 10% by weight, and most preferably 0.0001 to 5% by weight, based on the total weight of the composition. If the content of the complex extract is less than 0.00001% by weight, the skin itching relief effect, which is the object of the present invention, can not be obtained. If the content is more than 15% by weight, the effect is not proportional to the content, There is a problem that the stability of the shape is not ensured.

The composition containing the complex extract of the present invention exhibits a skin itching relieving and inhibiting effect and is almost free from cytotoxicity as a natural substance.

According to one embodiment of the present invention, in order to improve the relieving or inhibiting effect of skin itching, one or more extracts selected from the group consisting of chamomile, golden, licorice, green tea, May be further included.

According to one embodiment of the present invention, there is provided a cosmetic composition comprising a complex extract as an active ingredient.

The cosmetic composition according to the present invention may further contain, in addition to the complex extract as an active ingredient, conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers which are conventionally added to cosmetic compositions .

The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream.

When the formulation of the present invention is a paste, cream or gel, use is made of an animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide .

When the formulation of the present invention is a powder or a spray, tosse, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, chlorofluorohydrocarbons, propane / Propane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Castellulose, aluminum metahydroxide, bentonite, agar or tracert, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.

According to one embodiment of the present invention, there is provided a pharmaceutical composition comprising a complex extract as an active ingredient.

The pharmaceutical composition according to the present invention includes a pharmaceutically acceptable carrier in addition to the complex extract. The pharmaceutically acceptable carrier to be contained in the pharmaceutical composition of the present invention is one usually used at the time of formulation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc., in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably applied by parenteral administration, more preferably topical application by application.

A suitable dosage of the pharmaceutical composition of the present invention may vary depending on such factors as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate, . The dosage of the pharmaceutical composition of the present invention is in the range of 0.001-100 mg / kg on an adult basis. When the composition is an external preparation, it is preferably applied in an amount of 1.0 to 3.0 ml on an adult basis once to five times a day, and continued for 1 month or more. However, the dose is not intended to limit the scope of the present invention.

The pharmaceutical composition of the present invention may be prepared in unit dosage form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art, Into the container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in an oil or aqueous medium, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

According to a specific embodiment of the present invention, it has been confirmed that the cumulative stimulation of the complex extract results in harmless substances to the human body with little toxicity and side effects, and can be safely used even in long-term use. In particular, And can safely be used in pharmaceutical compositions.

As described above, the composition comprising the complex extract of the corn husks and the ground portion of the present invention as an active ingredient inhibits the release of histamine and the activation and expression of TRPV1 and IL-31 induced from the itching mediator, Thereby exhibiting an effect of alleviating and suppressing skin itching. In addition, the compound extract has been effective in measuring the atopic dermatitis index and the itching relieving degree in the human body application test, and can be safely used in cosmetic and pharmaceutical compositions since it has no adverse effects on human body.

FIG. 1 is a graph showing the inhibitory effect of histamine-free inhibiting effect of a combination extract containing corn husks and topical extracts of corn cobs.
FIG. 2 is a graph showing the effect of inhibiting the expression of IL-31 in a complex extract containing a corn husk and an extract of a groundwort plant.

Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.

Example 1: Alleviation of skin itching and selection of natural products having anti-inflammatory activity

Based on the previous studies on skin itch, we selected corn husks and chillies, and examined the skin itching relief and anti - inflammatory efficacy of the extracts obtained from them.

1-1. Manufacture of corn husk extract

The corn husk was sampled, washed, shredded and ground to a particle size of less than 1 mm. Then, 1 kg of pulverized corn husk powder was immersed in 10 liters of 70% ethanol and sonicated for 24 hours. Then, the obtained extract was filtered through a filter paper (No. 2, Advantec, USA) and lyophilized to prepare an extract powder.

1-2. Preparation of topical extract of Bacillus sp.

The shrubs were collected, shaved and shredded to a particle size of 1 mm or less. Then, 1 kg of the ground powder of crushed corn borer was dipped in 10 liters of 70% ethanol and sonicated for 24 hours. Then, the obtained extract was filtered through a filter paper (No. 2, Advantec, USA) and lyophilized to prepare an extract powder.

1-2-1. Fractionation of Bacillus thuringiensis Extract with Increased Asian Ticoside B Content

The topical extract of Bacillus thuringiensis including A. ticoside B was prepared by HPLC. The mobile phase was prepared by dissolving 400 mg of 70% ethanol extract of Centella asiatica in methanol (100 ml) and 0.45 μm membrane filtration , and the mobile phase was eluted with methanol / water (50:50, v / v) containing 4 mmol / l β-cyclodextrin The HPLC was performed using a Phenomenex Luna C18 (2), 5 μm column and a flow rate of 1 ml / min at 215 nm using a HPLC (Waters 600 controller, 616 pump, 717 autosampler, and 996 photodiode array detector) The fraction of the topical extract of Bacillus subtilis containing the Asian thioside B separated through the column was completely dried and then lyophilized and powdered.

1-3. Production of complex extract containing corn husk extract and topical extract

The corn husk extracts 1-1 and 1-2 of the above-mentioned topical extracts were mixed at a weight ratio of 1: 1 to prepare a combined extract.

1-4. Production of complex extract containing corn husk extract and fraction of topical extract

The extract of corn husk of 1-1 and the fraction of 1-2-1 of the topical extract of Bombyx mori were mixed at a weight ratio of 1: 1 to prepare a complex extract.

Example 2: in vitro Of histamine-inhibiting effect of complex extracts

Histamine glass inhibition was measured in order to investigate the effect of each extract and compound extract on histamine, a major factor inducing skin allergy. Specifically, mouse mast cell line (ATCC), a mouse mast cell, was cultured in a DMEM medium containing 10% Rat T-STIM, 10% FBS and 0.05 mM 2-mercaptoethanol, (2 x 10 ⁵ cells / well) and cultured in a 5% CO ₂ incubator at 37 ° C for 24 hours. Each of the cultured wells was pretreated with each extract and complex extract for 1 hour, then treated with 500 nM of A23187 (Sigma, USA) and re-cultured for 24 hours. After culturing for 24 hours, the cell culture supernatant was removed and centrifuged to collect only the supernatant.

The amount of histamine liberated was measured using a histamine ELISA kit (Enzo, USA). Detailed procedures were performed according to the Enzo kit manual. The amount of histamine liberated was compared with the histamine standard curve, and the result was shown in Fig.

FIG. 1 is a graph showing the inhibitory effect of histamine-free inhibiting effect of a combination extract containing corn husks and topical extracts of corn cobs. As shown here, the combined extract of corn extract (1-1), corncobs, corncobs extract, corncobs extract, and corncobs extract combined with the A23187-treated group, a positive control group, While the combined extracts of the extracts of corn husk extract + corn bark and ground corn extract showed markedly improved histamine release.

Example 3: in vitro Inhibition of TRPV1 Activity by Combined Extracts

The HEK293-TRPV1 cell line was inoculated on a 96-well black plate at 3 x 10 ⁴ cells / well and cultured for 24 hours. Twenty-four hours later, the cells were washed twice with HBSS (Hanks' Blanced Salt Solution) buffer, and then Fluo-4 was added to the cells. After incubation at 37 ° C for 30 minutes and at room temperature for 30 minutes, the cells were washed twice with HBSS buffer, and the extracts and complex extracts were treated with cells at different concentrations. After 10 minutes of reaction, capsaicin was treated and the change of intracellular Ca ²⁺ concentration was measured for 60 seconds. Intracellular Ca ²⁺ concentration was measured by fluorescence emission at a wavelength of 516 nm when excited with a wavelength of 494 nm. The difference between the minimum value and the maximum value obtained by measuring the flex of 60 seconds after the capsaicin treatment was obtained and then the difference was compared with the difference between the minimum value and the maximum value in the treatment of each extract and compound extract, The percent inhibition against intracellular entry is shown in Table 1 below.

Treating material TRPV1 activity inhibition (%) Capsaicin (control) - Corn bark extract (1-1) 10 ppm 2 100 ppm One 200 ppm 5 Bacillus subtilis extract (1-2) 10 ppm 3 100 ppm 5 200 ppm 7 Fraction of above-ground portion extract (1-2-1) 10 ppm 6 100 ppm 11 200 ppm 18 complex
extract Corn husk
+
Bacillus subtilis extract
(1-3) 10 ppm 8 100 ppm 12 200 ppm 17 Corn husk
+
Fraction of groundwort extract (1-4) 10 ppm 10 100 ppm 25 200 ppm 43

As shown in Table 1, there was almost no difference in the intracellular calcium ion inflow by capsaicin in the groups treated with the extracts of corn husks and topical extracts of corn cobs. In the fraction and complex extracts of corn borer, In the treatment conditions of complex extract of bark extract and topical extract of Bacillus subtilis, it showed weak calcium inhibitory activity. In particular, when the extract of corn husk extract and fraction of Bacillus subtilis extract was treated, Respectively.

From the above results, it was found that the combined extract of the corn husk extract and the fraction of the groundwort extract from the corn cob is effective in relieving symptoms of skin itching through TRPV1.

Example 4: in vitro Inhibition of IL-31 Expression by Combined Extracts

Peripheral blood mononuclear cells (PBMCs, ATCC® PCS-800-011 ™) were cultured in RPMI containing 5% human AB serum, 5 mmol / L glutamine, 1% penicillin / streptomycin, Plates were inoculated at 2 x 10 ⁶ cells / well and cultured for 24 hours. The test material is pretreated for 2 hours in each well and incubated for 24 hours with 1 ug / ml of Staphylococcal enterotoxin B (SEB, Sigma, USA). After 24 hours, the cells were recovered and RNA was extracted using an RNA extraction kit (RNeasy Mini kit, Qiagen, Germany), and cDNA was synthesized using a cDNA synthesis kit (amfiRivert Synthsis Platinum Master Mix, Gendepot, USA). The mRNA expression level of IL-31 was confirmed by real-time PCR using the synthesized cDNA of each condition. The PCR primers used are shown in Table 2 below.

gene Preemer Sequence (5 → 3) IL-31 forward GCC CAG CCG CCA AAC reverse GCT GTC TGA TTG TCT TGA GAT ATGC

Real-time PCR results of IL-31 performed under the above conditions are shown in FIG.

FIG. 2 is a graph showing the effect of inhibiting the expression of IL-31 in a complex extract containing a corn husk and an extract of a groundwort plant. As can be seen, the extracts of each of corn husk extract, corn husk extract, corn husk and corn husk and corn husk and corn rind extracts compared to the control SEB treatment group showed IL-31 In contrast, the combined extracts of corn husk extract and fraction of topical extract from the topical extracts showed excellent inhibition of IL-31 expression.

Example 5: Test for confirming safety of the complex extract on human skin

In order to confirm that the fraction of the topical extract of Bacillus subtilis showed efficacy on the human skin, a skin safety test was conducted on a complex extract containing a fraction of corn husk extract and bacillus subtilis extract. In order to verify skin safety, normal skin stimulation experiments were performed.

5-1. Manufacture of external skin preparation containing complex extract

In order to confirm that the complex extract containing the corn husk extract and the fraction of the topical extract of the bacillus subtilis was safe for the human skin, a skin external preparation containing the complex extract was prepared by the ingredients and contents shown in Table 3 below.

Specifically, purified water, glycerin, and butylene glycol were mixed and dissolved at 70 캜 (water part), and the other components except for the above three components and trimethanolamine were dissolved at 70 캜 (oil part). The oil part was added to a water part and stirred with a homomixer (Tokushu Kika, Japan) for primary emulsification, and trimethanolamine was finally added thereto. Next, the bubbles generated in the mixed solution were removed, and the mixture was cooled to room temperature to prepare an external preparation for skin. The composition of the composition for external application is shown in Table 3 below.

ingredient content (%) Control group Test group Purified water 72 71.9 glycerin 8.0 8.0 Butylene glycol 4.0 4.0 Complex extract 0 0.1 Caprylic Capri Triglyceride 8.0 8.0 Squalane 5.0 5.0 Cetearyl glucide 1.5 1.5 Sorbitan stearate 0.4 0.4 Cetearyl alcohol 1.0 1.0 Trimethanolamine 0.1 0.1 Gross weight 100 100

5-2. Experiment of cumulative stimulation of skin

The skin external preparation prepared in the above 5-1 was applied to 30 healthy adults for 9 times and 24 hours cumulative pelletization on the upper forearm every other day to determine whether or not the complex extract stimulates the skin.

A pin chamber (Finn chamber, Epitest Ltd, Finland) was used as a method of applying the coating, and 15 μl of each of the external preparations was dropped into the chamber. The degree of reaction on the skin each time was scored using the following equation (1), and the results are shown in Table 4.

A score of ±, a +, and a ++ is given as 1, 2, and 4, respectively, and a safe composition is determined when the average degree of reaction is less than 3.

Test substance Number of subjects who responded (persons) Average
Reactivity 1 week 2 weeks 3 weeks Primary Secondary Third Fourth 5th 6th Seventh 8th car 9th ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++
Control group
- / - / - - / - / - - / - / - - / - / - - / - / - - / - / - - / - / - - / - / - - / - / - 0.00 Complex extract
(200 ppm) - / - / - - / - / - - / - / - - / - / - - / - / - - / - / - - / - / - - / - / - - / - / - 0.00 Subject 30 30 30 30 30 30 30 30 30 0.00

As shown in Table 4, in the test group, the numbers of persons corresponding to ±, + and ++ were 0, 0, and 0, respectively, and the average reactivity was 0.00, 0.00, and 0.00, respectively. Therefore, the combined extracts were judged to be safe for human skin, which did not exhibit the cumulative stimulus pattern, because the average degree of reactivity was 3 or less.

An example of a preparation for a composition comprising a corn husk extract of the present invention and a complex extract comprising a fraction of a topical extract of a pathogenic fungus is provided below.

Formulation Example 1: Cosmetic preparation

1-1. Softening longevity

ingredient weight% Complex extract 0.01 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 ethanol 10.0 Triethanolamine 0.1 Preservatives, micronutrients, trace fragrances and trace water 82.79 sum 100.0

1-2. Nutritional lotion

ingredient weight% Complex extract 0.01 Wax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 5.0 Squalane 5.0 Caprylic / capric triglyceride 5.0 glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinyl polymer 0.1 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water 69.69 sum 100.0

1-3. Nourishing cream

ingredient weight% Complex extract 0.01 Wax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 10.0 Squalane 5.0 Caprylic / capric triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water 56.79 sum 100.0

1-4. Massage cream

ingredient weight% Complex extract 0.01 Wax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalane 5.0 Caprylic / capric triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water 27.49 sum 100.0

1-5. pack

ingredient weight% Complex extract 0.01 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 Allantoin 0.1 ethanol 5.0 Nonyl phenyl ether 0.3 Preservatives, micronutrients, trace fragrances and trace water 81.39 sum 100.0

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Example 6: in-vivo Measures for relieving itchiness of cosmetics containing complex extracts

Clinical efficacy was assessed on the basis of 33 subjects who had itching due to dry skin. After 8 weeks of corn bark extract and complex extract containing the fraction of topical extract of Bacillus subtilis, The results of this study were as follows. The rate of SCORAD (Scoring atopic dermatitis) and the visual analogue scale (VAS), which is a measure of pain itching, and the rate of change were measured by applying it to atopic dermatitis, a representative disease that causes skin itching.

The cream containing the complex extract was prepared by the method of Preparation Example 1-3, and then 33 creams were used for 2 weeks for 8 weeks. As a control, the cream prepared by the method of Preparation Example 1-3 containing purified water was used instead of the complex extract. The values are shown in Table 10 below.

division Itching Assessment (VAS) (Mean ± SD) Before use 36.82 + - 11.45 Control group change rate After 4 weeks of use 30.52 + - 10.75 After 8 weeks of use 28.69 ± 15.46 Before use - 4 weeks after use 17.11% Before use - After 8 weeks of use 22.08% Test group change rate After 4 weeks of use 26.08 ± 13.52 After 8 weeks of use 18.39 ± 12.16 Before use - 4 weeks after use 29.11% Before use - After 8 weeks of use 50.05% Rate of change (%) Control group (4 weeks) 12% Control group (8 weeks) 28%

As a result of the experiment, it was confirmed that the atopy index was improved by 12% when the condition of the cream without the compound extract as the control group and the condition of the cream containing the compound extract of the test group were compared with each other for 8 weeks, and the degree of pain itching was 28 % Improvement.

Claims (7)

A corn husk and a topical extract of Bacillus subtilis are mixed at a weight ratio of 2: 1 to 1: 2 as an active ingredient. The method according to claim 1,
Wherein the topical extract of Bacillus subtilis is a fraction of topical extract of Bacillus subtilis containing Asian thioside B. 3. The method of claim 2,
Characterized in that the fraction of the topical extract of Bacillus cereus is obtained by dissolving the Bacillus subtilis extract in an organic solvent and filtering and then performing a high performance liquid chromatography (HPLC) using an organic solvent and water as a mobile phase. Cosmetic composition. The method according to claim 1,
Wherein the skin itching is an itch caused by at least one of inflammatory dermatitis, atopic dermatitis, contact dermatitis, psoriasis, dry skin, seborrheic dermatitis, and ultraviolet rays. The method according to claim 1,
Wherein the composition further comprises at least one extract selected from the group consisting of chamomile, golden, licorice, green tea, shellac, and rosemary extract. The method according to claim 1,
The cosmetic composition for suppressing or alleviating skin itching according to claim 1, wherein the complex extract is 0.00001 to 15% by weight based on the total weight of the composition. Corn husks and topical extracts of Bacillus subtilis in a weight ratio of 2: 1 to 1: 2 as an active ingredient.

Images